Cahill Wealth Management’s Viking Therapeutics VKTX Stock Holding History

Cahill Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$514K	Buy	21,286 +5,991	+39%	+$189K	0.26%	36
2024 Q4	$615K	Buy	15,295 +1,515	+11%	+$86.4K	0.31%	33
2024 Q3	$872K	Buy	13,780 +1,196	+10%	+$70.2K	0.45%	27
2024 Q2	$667K	Buy	12,584 +2,738	+28%	+$179K	0.4%	29
2024 Q1	$807K	Buy	+9,846	New	+$438K	0.47%	30

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Cahill Wealth Management's VKTX Position: Q1 2025 in Review

Cahill Wealth Management increased its Viking Therapeutics (VKTX) stake by 39% in Q1 2025, buying an estimated $189K and bringing the position to 21,286 shares worth $514K. The position accounts for 0.26% of the portfolio, ranked #36.

Cahill Wealth Management first reported a position in VKTX in Q1 2024 and has held it in 5 quarters since. The position peaked at $872K in Q3 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

Cahill Wealth Management held 21,286 shares of Viking Therapeutics worth $514K as of Q1 2025.
Cahill Wealth Management bought 5,991 Viking Therapeutics shares in Q1 2025, an estimated $189K.
Viking Therapeutics made up 0.26% of Cahill Wealth Management's portfolio in Q1 2025, its #36 holding.
Cahill Wealth Management first reported a position in Viking Therapeutics in Q1 2024 and has held it in 5 quarters since.
Cahill Wealth Management's Viking Therapeutics position peaked at $872K in Q3 2024.
372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Cahill Wealth Management's 13F filing for Q1 2025, filed 12 May 2025.